Skye Bioscience Inc. (SKYE)
NASDAQ (NMS) NASDAQ (NMS) Primary 
XMUN 
Lost Money on Skye Bioscience, Inc.(SKYE)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / August 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Skye Bioscience, Inc. ("Skye") (NASDAQ:SKYE) concerning possible violations of federal securities laws. Skye issued a press release on June 10, 2024, "announc[ing] that its Phase 2a clinical trial of SBI-100 Ophthalmic Emulsion ("OE") in patients with primary open-angle glaucoma "POAG") or ocular hypertension ("OHT") did not meet its primary endpoint for lowering intraocular pressure ("IOP").
Skye Bioscience Inc Investors Are Eligible To Join Fraud Investigation With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 7, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Skye Bioscience, Inc. ("Skye" or "the Company") (NASDAQ: SKYE ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Skye Bioscience, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - SKYE
NEW YORK, NY / ACCESSWIRE / August 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Skye Bioscience, Inc. ("Skye") (NASDAQ:SKYE) concerning possible violations of federal securities laws. Skye issued a press release on June 10, 2024, "announc[ing] that its Phase 2a clinical trial of SBI-100 Ophthalmic Emulsion ("OE") in patients with primary open-angle glaucoma "POAG") or ocular hypertension ("OHT") did not meet its primary endpoint for lowering intraocular pressure ("IOP").
Skye Bioscience, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- SKYE
NEW YORK, NY / ACCESSWIRE / August 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Skye Bioscience, Inc. ("Skye") (NASDAQ:SKYE) concerning possible violations of federal securities laws. Skye issued a press release on June 10, 2024, "announc[ing] that its Phase 2a clinical trial of SBI-100 Ophthalmic Emulsion ("OE") in patients with primary open-angle glaucoma "POAG") or ocular hypertension ("OHT") did not meet its primary endpoint for lowering intraocular pressure ("IOP").
Skye Bioscience Inc Investors Can Participate In Fraud Investigation With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 6, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Skye Bioscience, Inc. ("Skye" or "the Company") (NASDAQ: SKYE ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Skye Bioscience, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- SKYE
NEW YORK, NY / ACCESSWIRE / August 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Skye Bioscience, Inc. ("Skye") (NASDAQ:SKYE) concerning possible violations of federal securities laws. Skye issued a press release on June 10, 2024, "announc[ing] that its Phase 2a clinical trial of SBI-100 Ophthalmic Emulsion ("OE") in patients with primary open-angle glaucoma "POAG") or ocular hypertension ("OHT") did not meet its primary endpoint for lowering intraocular pressure ("IOP").
Skye Bioscience, Inc. (SKYE) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights
NEW YORK, NY / ACCESSWIRE / August 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Skye Bioscience, Inc. ("Skye") (NASDAQ:SKYE) concerning possible violations of federal securities laws. Skye issued a press release on June 10, 2024, "announc[ing] that its Phase 2a clinical trial of SBI-100 Ophthalmic Emulsion ("OE") in patients with primary open-angle glaucoma "POAG") or ocular hypertension ("OHT") did not meet its primary endpoint for lowering intraocular pressure ("IOP").
Skye Bioscience, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - SKYE
NEW YORK, NY / ACCESSWIRE / August 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Skye Bioscience, Inc. ("Skye") (NASDAQ:SKYE) concerning possible violations of federal securities laws. Skye issued a press release on June 10, 2024, "announc[ing] that its Phase 2a clinical trial of SBI-100 Ophthalmic Emulsion ("OE") in patients with primary open-angle glaucoma "POAG") or ocular hypertension ("OHT") did not meet its primary endpoint for lowering intraocular pressure ("IOP").
Did Skye Bioscience, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - SKYE
NEW YORK, NY / ACCESSWIRE / August 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Skye Bioscience, Inc. ("Skye") (NASDAQ:SKYE) concerning possible violations of federal securities laws. Skye issued a press release on June 10, 2024, "announc[ing] that its Phase 2a clinical trial of SBI-100 Ophthalmic Emulsion ("OE") in patients with primary open-angle glaucoma "POAG") or ocular hypertension ("OHT") did not meet its primary endpoint for lowering intraocular pressure ("IOP").
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Skye Bioscience, Inc. (SKYE)
NEW YORK, NY / ACCESSWIRE / August 3, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Skye Bioscience, Inc. ("Skye") (NASDAQ:SKYE) concerning possible violations of federal securities laws. Skye issued a press release on June 10, 2024, "announc[ing] that its Phase 2a clinical trial of SBI-100 Ophthalmic Emulsion ("OE") in patients with primary open-angle glaucoma "POAG") or ocular hypertension ("OHT") did not meet its primary endpoint for lowering intraocular pressure ("IOP").
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Skye Bioscience, Inc. (SKYE)
NEW YORK, NY / ACCESSWIRE / August 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Skye Bioscience, Inc. ("Skye") (NASDAQ:SKYE) concerning possible violations of federal securities laws. Skye issued a press release on June 10, 2024, "announc[ing] that its Phase 2a clinical trial of SBI-100 Ophthalmic Emulsion ("OE") in patients with primary open-angle glaucoma "POAG") or ocular hypertension ("OHT") did not meet its primary endpoint for lowering intraocular pressure ("IOP").
Skye Bioscience, Inc. (SKYE) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights
NEW YORK, NY / ACCESSWIRE / August 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Skye Bioscience, Inc. ("Skye") (NASDAQ:SKYE) concerning possible violations of federal securities laws. Skye issued a press release on June 10, 2024, "announc[ing] that its Phase 2a clinical trial of SBI-100 Ophthalmic Emulsion ("OE") in patients with primary open-angle glaucoma "POAG") or ocular hypertension ("OHT") did not meet its primary endpoint for lowering intraocular pressure ("IOP").
